Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations

Jérémie Botton; Laura Semenzato; Marie-Joëlle Jabagi; Bérangère Baricault; Alain Weill; Rosemary Dray-Spira; Mahmoud Zureik

doi:10.1001/jamanetworkopen.2022.0868

Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations

JAMA Netw Open. 2022 Mar 1;5(3):e220868. doi: 10.1001/jamanetworkopen.2022.0868.

Authors

Jérémie Botton¹, Laura Semenzato¹, Marie-Joëlle Jabagi¹, Bérangère Baricault¹, Alain Weill¹, Rosemary Dray-Spira¹, Mahmoud Zureik¹

Affiliation

¹ EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, Saint-Denis, France.

Abstract

This comparative effectiveness research study examines the effectiveness of full vaccination with Ad26.COV2.S vs BNT162b2 against COVID-19–related hospitalization.

Publication types

Comparative Study
Letter

MeSH terms

Ad26COVS1 / therapeutic use*
Aged
Aged, 80 and over
BNT162 Vaccine / therapeutic use*
COVID-19 / prevention & control*
COVID-19 Vaccines / administration & dosage*
Comparative Effectiveness Research
Female
France / epidemiology
Hospitalization*
Humans
Male
Middle Aged
Population Health
SARS-CoV-2 / immunology*
Vaccine Efficacy*

Substances

Ad26COVS1
COVID-19 Vaccines
BNT162 Vaccine